In the ADDITION-Cambridge population-based study, 30% of participants achieved remission of T2DM after 5 years, mostly those who lost ≥10% body weight early in the T2DM disease trajectory.

EASD 2019 Study shows that both natural variation in ACE concentrations and lowering blood pressure with ACE inhibitors are associated with lower risk of type 2 diabetes.

EASD 2019 The VERIFY trial demonstrated that early combination therapy using vildagliptin and metformin was superior to a sequential approach involving later intensification in new T2DM

ESC 2019 As a consequence of recent outcome trials of new therapies for diabetes, new treatment recommendations now include use of SGLT2 inhibitors and GLP-1RA.

Adults with clinically normal risk factor profiles, who were randomized to a 25% calorie restriction intervention for 2 years, showed improved insulin sensitivity and metabolic syndrome scores.

EuroPrevent 2019 Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how can we modify CVD risk factors in these patients.

EuroPrevent 2019 Prof. Jacobs discusses the shift in management of diabetes based on CVOTs and explains underlying mechanisms of benefits with GLP-1RAs in diabetic patients.

EuroPrevent 2019 Prof. Deanfield reflects on a new era in CVD prevention for patients with diabetes. He discusses how can we prevent diabetes and manage diabetes exposure in the general population.

In a follow-up study of VADT, original intensive glucose lowing over 5.6 years did not result in improved outcomes in T2DM patients vs. standard-therapy after 15 years, providing no evidence of a legacy effect.

EPCCS 2019 Profs Khunti and Hobbs discuss why CV risk needs attention in patients with diabetes, and how this can be mitigated. They also consider barriers that prevent optimal implementation of the evidence on effective management strategies.

An analysis of the ADVANCE study shows that the treatment effect of perindopril-indapamide in patients with diabetes is independent of SBP, DBP or 10-year ASCVD risk at baseline.

EPCCS 2019 Read impressions of the updates on stroke prevention in AF, hypertension, HF and CV risk in diabetes, with emphasis on challenges faced in patients with multimorbidities.